The CRL outcome and Type A meeting results are the key near-term catalysts. The company has sufficient cash to fund operations through the resubmission process, but the warrant overhang (4.4M shares at $3.395) creates dilution risk if the NDA is approved. Monitor for Type A meeting minutes and any subsequent NDA resubmission timeline.
Price Chart
Executive Summary
Grace Therapeutics filed an 8-K attaching its June 2026 corporate presentation, which provides an update on the FDA Complete Response Letter (CRL) for its lead drug candidate GTx-104 (intravenous nimodipine for aSAH). The CRL was driven by CMC data package completeness and manufacturing readiness issues, with no clinical deficiencies identified. The company has scheduled a Type A meeting with the FDA and intends to resubmit the NDA. The presentation also highlights positive Phase 3 STRIVE-ON trial data showing clinical, pharmacoeconomic, and dosing benefits over oral nimodipine, and notes a cash balance of $17.0M as of March 31, 2026.
Key Facts
- FDA Complete Response Letter received in April 2026 for GTx-104 NDA; no clinical deficiencies identified
- CRL driven by CMC data package completeness and manufacturing readiness; Type A meeting scheduled
- Pivotal Phase 3 STRIVE-ON safety trial met primary endpoint; 29% relative increase in good recovery at 90 days vs oral capsules
- 19% relative reduction in clinically significant hypotension vs oral capsules
- 54% of GTx-104 patients received >95% prescribed dose vs 8% on oral capsules
- Cash balance of $17.0M as of March 31, 2026
- Outstanding warrants with aggregate exercise price of ~$15.0M at $3.395/share, expiring on earlier of 60 days post-FDA approval or Sept 2028
- No debt on balance sheet
Financial Impact
Cash position of $17.0M; potential $15.0M gross proceeds from warrant exercise upon NDA approval
Risk Factors
- FDA may require additional clinical or non-clinical studies beyond those identified in the CRL
- Manufacturing facility remediation at CDMO may delay or complicate approval
- Warrant exercise proceeds are contingent on NDA approval and may not materialize if approval is delayed or denied
- Small market cap ($30M) and low cash runway relative to development stage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-025669 |
| Document: ef20076431_form8k.htm | 0001140361-26-025669 |
| Document: 0001140361-26-025669-index-headers.html | 0001140361-26-025669 |
| Document: 0001140361-26-025669-index.html | 0001140361-26-025669 |
| Document: 0001140361-26-025669.txt | 0001140361-26-025669 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Insider Cluster | $2.26 $2.22 | ▼ −1.77% | ▼ −2.62% | $1.93 (−14.60%) |
Aug 13, 2026 10w ago | 8-K | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 13, 2026 10w ago | Press Release | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 4, 2026 11w ago | Press Release | $2.14 $2.12 | ▼ −0.93% | ▼ −0.77% | $1.93 (−9.81%) |
Jul 28, 2026 12w ago | 8-K | $2.25 $2.08 | ▼ −7.56% | ▼ −6.02% | $1.93 (−14.22%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▼ −5.04% | ▼ −4.73% | $1.93 (−18.91%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 18, 2026 18w ago | Press Release | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 5, 2026 20w ago | 8-K | $2.30 $2.33 | ▲ +1.30% | ▲ +1.60% | $1.93 (−16.09%) |
Apr 27, 2026 26w ago | 8-K | $2.16 $2.10 | ▲ +2.78% | ▲ +2.29% | $1.93 (+10.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers